Partners develop enhanced formulation of obesity candidate
Arecor Therapeutics and Skye Bioscience have agreed a formulation development collaboration to develop a novel, higher concentration formulation of Skye’s CB1 inhibitor, nimacimab. Skye is evaluating nimacimab, a first-in-class CB1-inhibiting monoclonal antibody, in its Phase IIa CBeyond clinical trial in patients with obesity and overweight. Data from… Read More